Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

JCR Pharmaceuticals : US FDA grants Fast Track Designation for JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPSI)
JCR Pharmaceuticals : US FDA grants Fast Track Designation for JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPSI)
Oct.
Two Americans win Medicine Nobel for work on heat and touch
Two Americans win Medicine Nobel for work on heat and touch
STOCKHOLM, Oct 4 (Reuters) - American scientists David Julius and Ardem Patapoutian won the 2021 Nobel Prize for Medicine on Monday for the discovery of receptors in the skin that sense temper...
Latest FDA-Approved Preventive Treatment For Migraine, Qulipta, Enters A Highly Competitive Market
Latest FDA-Approved Preventive Treatment For Migraine, Qulipta, Enters A Highly Competitive Market
On September 28th, the Food and Drug Administration (FDA) approved a once-daily oral medicine, Qulipta (atogepant), for preventive treatment of episodic migraine in adults.
DiaMedica Therapeutics Announces Fast Track Designation Granted To DM199 For The Treatment Of Acute Ischemic Stroke
DiaMedica Therapeutics Announces Fast Track Designation Granted To DM199 For The Treatment Of Acute Ischemic Stroke
DiaMedica Therapeutics Inc.
Narsoplimab FDA Approval Status
Narsoplimab FDA Approval Status
Narsoplimab is an investigational human monoclonal antibody in development for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc.
Mirum's oral drug becomes first U.S. approved Alagille syndrome therapy
Mirum's oral drug becomes first U.S. approved Alagille syndrome therapy
Sept 29 (Reuters) - Mirum Pharmaceuticals Inc (MIRM.
Pfizer COVID-19 Vaccine Might Not Be Authorized for Young Children Until November
Pfizer COVID-19 Vaccine Might Not Be Authorized for Young Children Until November
Pfizer’s and BioNTech’s COVID-19 vaccine may not receive FDA authorization for children ages five to 11 until November, as the companies have yet to submit a revised Emergency Use Application (...
FDA Approves AbbVie’s Migraine-Prevention Drug Qulipta
FDA Approves AbbVie’s Migraine-Prevention Drug Qulipta
AbbVie’s Qulipta Set to Become Blockbuster in the Migraine Market.
Pacira BioSciences begins commercial production of EXPAREL at Swindon facility
Pacira BioSciences begins commercial production of EXPAREL at Swindon facility
Pacira BioSciences (NASDAQ.
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2021 / Jaguar Health, Inc.
Catalyst wins favorable court ruling on orphan drug
Catalyst wins favorable court ruling on orphan drug
Catalyst Pharmaceuticals (NASDAQ.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand